Offering Buprenorphine Prior to Release from Jail May Reduce Recidivism

Findings from JCOIN’s Massachusetts Research Hub Individuals leaving incarceration with opioid use disorder (OUD) are at a high risk for overdose, recidivism, and adverse health outcomes. Providing medication for opioid use disorder (MOUD) prior to incarceration and post-release is effective in reducing negative outcomes. Existing studies tend to examine how the use of methadone and/or…

Read More

Issue Brief: Medications for Opioid and Alcohol Use Disorders: Research Insights for Criminal Justice Professionals

Key Takeaways Medications for Substance Use Disorders Are Effective Treatments. Methadone, buprenorphine, and naltrexone are FDA-approved medications for the treatment of opioid use disorder (OUD). Naltrexone, acamprosate, and disulfiram are FDA-approved medications for the treatment of alcohol use disorder (AUD). These medications are effective in reducing substance use and improving recovery outcomes. Patient Choice Matters.…

Read More

Issue Brief: Treating Opioid Use Disorder in Justice-Involved Populations

Download the Issue Brief (PDF) Opioid use disorder (OUD) is a medical condition that is treatable. Individuals involved in the criminal justice system should be screened for OUD. Anyone with moderate to severe OUD should have access to medication treatment for OUD in all criminal justice settings and upon release. OUD is a treatable illness,…

Read More

Justice-Involved Individuals Returning to the Community are at High Risk for Overdose Fatality within First Two Weeks after Release from Incarceration; Research Shows MAT Reduces Risk by 75%

Features & News In 2018, over 67,000 Americans died from drug overdoses and opioid overdose fatalities rose by 10 percent from the previous year.1 Nearly 11 million individuals passing through the criminal justice system every year and they are one of the most vulnerable groups exposed to the drug crisis.2 In separate studies conducted in…

Read More